Toggle light / dark theme

When not all men and women are created equal.


If futurist, inventor, and Google executive Ray Kurzweil is right about the future, we’ll all be augmenting our brains with extra capacity in the cloud at some point in the future.

Which sounds exciting, even if a little frightening.

But this very advance could also pave the way for the rich to become thousands of times smarter than poor people, which would likely permanently solidify and even exacerbate current socioeconomic stratifications. I asked Kurzweil if he saw that consequence as a possibility, and he strongly disagreed.

Quantum computers promise speedy solutions to some difficult problems, but building large-scale, general-purpose quantum devices is a problem fraught with technical challenges.

To date, many research groups have created small but functional computers. By combining a handful of atoms, electrons or superconducting junctions, researchers now regularly demonstrate quantum effects and run simple —small programs dedicated to solving particular problems.

But these laboratory devices are often hard-wired to run one program or limited to fixed patterns of interactions between the quantum constituents. Making a quantum computer that can run arbitrary algorithms requires the right kind of physical system and a suite of programming tools. Atomic , confined by fields from nearby electrodes, are among the most promising platforms for meeting these needs.

Read more

Exciting news today about the new smaller reprogrammable QC discovery; however, in China.


Scientists in China are set to launch the world’s first ‘quantum satellite,’ which could one day make for an ultra-secure global communications network.

The 1,300 pound craft contains a crystal that produces pairs of entangled photons, which will be fired to ground stations in China and Austria to form a ‘secret key.’

Made in China motto is gaining speed in China.


SHANGHAI Foreign firms say they are struggling to gain access to China’s vast railway market as the country, seeking to transform its domestic industry into an export powerhouse, tightens the bidding criteria on rail tenders.

The complaints echo similar concerns raised in other industries including technology and renewable energy, and highlight what some foreign companies see as an uneven playing field when operating in China.

Four rail suppliers with offshore funding said they were finding it harder to win contracts thanks to the proliferation of government-supported rivals, with at least one saying it was already experiencing discrimination.

Fixing one thing only gets you so far, as all the other forms of damage will still, on their own, kill you. Aubrey de Grey of the SENS Research Foundation believes that only small gains in overall life span are possible without addressing all of the causes of aging.


Five years from now, it will be possible to take a trip overseas to have most of the senescent cells that have built up in your tissues cleared away via some form of drug or gene therapy treatment. That will reduce your risk of suffering most age-related diseases, and in fact make you measurably younger — it is a narrow form of rejuvenation, targeting just one of the various forms of cell and tissue damage that cause aging, age-related disease, and ultimately death. I say five years and mean it. If both of the present senescent cell clearance startup companies Oisin Biotechnologies and UNITY Biotechnology fail rather than succeed, and it is worth noting that the Oisin founders have a therapy that actually works in animal studies, while drugs and other approaches have also been shown to both clear senescent cells and extend life in mice, then there will be other attempts soon thereafter. The basic science of senescent cell clearance is completely open, and anyone can join in — in fact the successful crowdfunding of the first Major Mouse Testing Program study earlier this year was exactly that, citizen scientists joining in to advance the state of the art in this field.

Five years from now, however, there will be no definitive proof that senescent cell clearance extends life in humans, nor that it reduces risk of age-related disease in our species over the longer term. There will no doubt be a few more studies in mice showing life extension. There will be initial human evidence that clearance of senescent cells causes short-term improvements in technical biomarkers of aging such as DNA methylation patterns, or more easily assessed items such as skin condition — given how much of the skin in old people is made up of senescent cells — or markers of chronic inflammation. These are all compelling reasons to undertake the treatment, but if you want definite proof of life extension you’ll have to wait a decade or more beyond the point of first availability, as that is about as long as it takes to put together and run academic studies that make a decent stab at quantifying effects on mortality in old people.

Uncertainty is the state of affairs when considering the effects of potentially life-extending therapies on human life span. Consider the practice of calorie restriction, for example, where theory suggests the likely outcome is a few extra years, but certainly not a large number of extra years or else it would be very apparent in epidemiological data. I think that an enterprising individual could, given a good relationship with the Calorie Restriction Society, put together a 20-year or 40-year study to that would — in theory — produce a decent set of data on practitioners and outcomes in the wild. It won’t happen, most likely, because for one the funding isn’t there for such a study, and secondly we’ll be well into the era of widely available rejuvenation therapies along the way. Those calorie restriction practitioners will be taking advantage of treatments to repair the causes of aging just like everyone else.

An interview with SENS research Dr. Haroldo Silva and his work with ALT Cancer.


As you might have noticed, the SENS Research Foundation is presently asking for your support in a crowdfunding campaign that aims to close in on a universal therapy capable of effectively treating all types of cancer, one based on blocking telomere lengthening. As is often the case, the SENS network is here using philanthropic donations to pick up necessary work that hasn’t been taken on by the rest of the community, so as to unblock progress. The scientist who will lead the work is Haroldo Silva; he has been focused on this particular branch of cancer research for some years now, and below you’ll find a short interview that covers some of his thoughts on the field and on this effort in particular.

I should emphasize that this SENS initiative is an important component in efforts to completely change the way in which the research community approaches the treatment of cancer. The cancer research community suffers from a high level strategy problem: the majority of treatments are only applicable to a small number of cancer types, out of the hundreds of known types, and the majority of new technology platforms under development will be just as expensive to adapt to a different type of cancer as to build in the first place. A much more efficient approach is needed, as there are only so many researchers and only so much funding in the world. As Silva describes below, blocking telomere lengthening is the most efficient of possible better approaches: all cancers must lengthen their telomeres in order to grow, and abuse a small number of target mechanisms in order to do so.

Read more